true that the trial by Calverley et al. provided 60% of the weight for the analysis of respiratory deaths associated with betaagonists compared with placebo. The data from this trial came from the publication itself, as well as from a published erratum and unpublished communication concerning the causes of death. 3, 4 We did not include the other trial by Calverley et al. in the analysis because the paper did not provide information on exacerbations or deaths. 5 After we submitted our paper for publication, we have since received unpublished information from this trial. In the future, this information could be combined with that of other trials to assess, for example, whether concomitant inhaled corticosteroids can protect against the adverse effects of beta-agonists. At this point, it is clinically more important to evaluate the effect of beta-agonists compared with anticholinergics, with or without corticosteroids, in the treatment of chronic obstructive pulmonary disease (COPD). We have pooled data from direct comparisons between the two types of bronchodilators and found that beta-agonists increased the risk for severe COPD exacerbations by twofold and total mortality by fivefold, compared with anticholinergics. 1, 6 These results indicate that anticholinergics should be the bronchodilator of choice in COPD.
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